MyScent Diagnostics
Early Cancer Detection Using Urine or Breath
Company Overview
Snapshot
Founded in May 2013 by Ilan Alfia and Michal Mark Danieli, MyScent Diagnostics operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing its core technology.
Business overview
MyScent Diagnostics is a Health Tech & Life Sciences company focused on developing solutions for the early detection of cancer. The company utilizes highly sensitive sensors to analyze volatile organic compounds in urine or breath samples, primarily targeting breast and lung cancer. While its initial focus is on cancer detection, the underlying technology has broader applications across various diseases. MyScent Diagnostics operates within the medical devices and diagnostics sectors, serving laboratories and healthcare providers.
Company Intelligence Q&A
- What is MyScent Diagnostics' core technology?
- MyScent Diagnostics develops a solution for early cancer detection using extremely sensitive sensors to test volatile organic compounds in patient urine or breath samples.
- What types of cancer does MyScent Diagnostics' technology target?
- MyScent Diagnostics' technology is primarily focused on the early detection of breast and lung cancer.
- When was MyScent Diagnostics founded?
- MyScent Diagnostics was founded in May 2013.
- Who are the founders of MyScent Diagnostics?
- MyScent Diagnostics was co-founded by Ilan Alfia and Michal Mark Danieli.
- What is the current product stage of MyScent Diagnostics?
- MyScent Diagnostics' product is currently in the R&D stage, as of its last update in December 2018, indicating ongoing development.